about
Gene sequence variations of the platelet P2Y12 receptor are associated with coronary artery diseaseLinkage analysis of 6p21 polymorphic markers and the hereditary hemochromatosis: localization of the gene centromeric to HLA-FLoss-of-function mutations in APOC3, triglycerides, and coronary diseaseHigh resolution preparation of monocyte-derived macrophages (MDM) protein fractions for clinical proteomicsMeasurement of urinary hepcidin levels by SELDI-TOF-MS in HFE-hemochromatosis.Combined effect of hemostatic gene polymorphisms and the risk of myocardial infarction in patients with advanced coronary atherosclerosis.Additive effect of LRP8/APOER2 R952Q variant to APOE epsilon2/epsilon3/epsilon4 genotype in modulating apolipoprotein E concentration and the risk of myocardial infarction: a case-control study.Deoxygenation affects tyrosine phosphoproteome of red cell membrane from patients with sickle cell disease.Hepcidin is not useful as a biomarker for iron needs in haemodialysis patients on maintenance erythropoiesis-stimulating agents.Abnormal modulation of cell protective systems in response to ischemic/reperfusion injury is important in the development of mouse sickle cell hepatopathy.A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status.A novel molecular diagnostic marker for familial and early-onset coronary artery disease and myocardial infarction in the LRP8 gene.DNA methylation and gene expression profiles show novel regulatory pathways in hepatocellular carcinoma.The RFC1 80G>A, among Common One-Carbon Polymorphisms, Relates to Survival Rate According to DNA Global Methylation in Primary Liver Cancers.Increased serum hepcidin levels in subjects with the metabolic syndrome: a population study.An LRP8 variant is associated with familial and premature coronary artery disease and myocardial infarction.Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease.Factor II activity is similarly increased in patients with elevated apolipoprotein CIII and in carriers of the factor II 20210A allele.A 'desaturase hypothesis' for atherosclerosis: Janus-faced enzymes in omega-6 and omega-3 polyunsaturated fatty acid metabolism.Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease.Thrombosis and sickle cell disease.Epigenetics and arterial hypertension: the challenge of emerging evidence.Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study.Fentanyl Buccal Tablet: A New Breakthrough Pain Medication in Early Management of Severe Vaso-Occlusive Crisis in Sickle Cell Disease.11β-Hydroxysteroid dehydrogenase type-2 and type-1 (11β-HSD2 and 11β-HSD1) and 5β-reductase activities in the pathogenia of essential hypertension.Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study.Multi-allelic haplotype association identifies novel information different from single-SNP analysis: a new protective haplotype in the LRP8 gene is against familial and early-onset CAD and MI.One-carbon genetic variants and the role of MTHFD1 1958G>A in liver and colon cancer risk according to global DNA methylation.Urinary prostasin: a candidate marker of epithelial sodium channel activation in humans.Development of interactive algorithm for clinical management of acute events related to sickle cell disease in emergency department.Correction: Increased Serum Hepcidin Levels in Subjects with the Metabolic Syndrome: A Population Study.Apolipoprotein C-III predicts cardiovascular mortality in severe coronary artery disease and is associated with an enhanced plasma thrombin generation.Effects of female sex hormones and contraceptive pill on the diagnostic work-up for primary aldosteronism.Aldosterone to Renin ratio in a primary care setting: the Bussolengo study.Increased factor VIII coagulant activity levels in male carriers of the factor V R2 polymorphism.Different impact of deletion polymorphism of gene on the risk of renal and coronary artery disease.A1298C methylenetetrahydrofolate reductase mutation and coronary artery disease: relationships with C677T polymorphism and homocysteine/folate metabolism.Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction.Detection of a large deletion in the P-selectin (SELP) gene.11β-hydroxysteroid dehydrogenase type 2 polymorphisms and activity in a Chilean essential hypertensive and normotensive cohort.
P50
Q28221103-CC588571-500D-4823-A097-42B2A7AFEF65Q28270349-8805FD16-76BA-4484-8A04-3B074CA5F2B2Q30408720-4CE816E7-1A46-41EF-9D4E-A9BE39A6DFBEQ30858573-EA0CF480-DDD7-460F-8539-B0842E1A840AQ33312715-FF34F61B-9BCC-44EC-9BD5-0B9CBECDCD40Q33318443-AB76FA86-ADFC-43F0-9CDE-846BBCDCAE2BQ33445395-4BA293E9-501F-4A71-9366-390904F775ECQ33537545-B1540628-F5EA-40BD-A9D8-A9658D0C06A4Q33600843-BC3DA304-C0C4-41CC-B42C-444888D9BDC9Q33695612-97646C7A-E544-4412-ABB8-EF0660F9BE99Q34025724-64DCFECE-435F-42CF-ABDF-637BC5621CBCQ34076234-2C644316-3C67-41FF-9085-B1B3B3336678Q35568894-81ED7B66-45A9-40CB-88AA-121F68C78415Q36217905-2AD16396-200F-4923-AF8D-16CA97600628Q36353620-822DD015-D397-44BC-A6B6-5DE59CDDA893Q36430809-B3367C52-5CD9-4AB0-B09D-DA2AF5C482BAQ36851336-00DD5474-4275-4153-AA79-016A3CB14AD0Q37457665-BCD0C3F7-DA0B-489C-AD47-AC153C31E44BQ37602474-2C943E58-DC0F-4776-AC05-A552FC07A560Q37648324-119638B8-1D1E-4CA7-91A0-3E1C8C3AB97CQ37860232-88C8AE1D-AEAD-48B5-BCD0-0F05915A127EQ38230822-EBDA1CCE-B93A-4AD4-8F41-59C5BD34E868Q38752767-30D8A3C4-32F3-434D-82AA-5CC02E312F61Q39188770-5D295C27-4096-482F-AE39-FB12F2106900Q39933267-83B6FE76-5A45-4FEC-A946-2857BF7F920EQ40809666-B105B224-CCA9-470B-92AF-1ADE138D555AQ41941614-A8BD68E9-ABDF-4288-9796-597441CD23FDQ42369000-4F0B1AD5-E8F1-49A3-B986-CD3599A1964FQ42484197-9320D283-E896-45EE-8F5F-EDD1E664F846Q43004271-FCAAF1A1-163A-4894-9354-18782D5363B3Q43114166-8126CB6A-CFA3-4113-A985-B526ABB9A623Q43225362-DA75208F-72C4-43D1-85C9-0BE216DEBF5EQ43232533-666CA84E-606E-45B9-B52E-CF93A5C2550CQ43652946-140FDA84-D737-4B73-8F02-259FB011F466Q43676503-CABFB1F1-BCA0-4F43-AC71-1FDCFC20D4CEQ43854492-DD3A27AF-FD93-4678-9F3D-B213432C86ACQ44017356-012743AD-8102-41D1-8617-C27DBA69EA49Q44776749-521B6865-9D6F-466B-9716-6D22F3BA0546Q45116143-A4FF339B-F17B-492C-957B-E529B9593475Q45142165-3E87A512-4970-4B98-85F5-E473496A7A35
P50
description
researcher
@en
researcher
@en-gb
wetenschapper
@nl
հետազոտող
@hy
name
Oliviero Olivieri
@ast
Oliviero Olivieri
@en
Oliviero Olivieri
@en-gb
Oliviero Olivieri
@es
Oliviero Olivieri
@nl
Oliviero Olivieri
@sl
type
label
Oliviero Olivieri
@ast
Oliviero Olivieri
@en
Oliviero Olivieri
@en-gb
Oliviero Olivieri
@es
Oliviero Olivieri
@nl
Oliviero Olivieri
@sl
altLabel
oliviero olivieri
@en
prefLabel
Oliviero Olivieri
@ast
Oliviero Olivieri
@en
Oliviero Olivieri
@en-gb
Oliviero Olivieri
@es
Oliviero Olivieri
@nl
Oliviero Olivieri
@sl
P106
P1153
7006990678
P31
P496
0000-0001-8209-9056